ExtraCorporeal Membrane Oxygenation Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Global ExtraCorporeal Membrane Oxygenation Market is segmented By Type (Venoarterial (VA) ECMO, Venovenous (VV) ECMO), By Age Group (Children, Adult), By Application (Respiratory, Cardiac, ECPR), By End User (Hospitals, Specialty Clinics, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030

ExtraCorporeal Membrane Oxygenation Market Overview

Global ExtraCorporeal Membrane Oxygenation Market is expected to reach at a high CAGR during the forecast period 2023-2030.

ExtraCorporeal Membrane Oxygenation, or ECMO for simpler terms, is also known as extracorporeal life support, or ECLS. When a person's natural organs are too sick to support the body, this treatment uses a man-made heart and lung to do it. People who have severe heart and lung diseases, need a heart transplant, or are recovering from a heart transplant may benefit from ECMO. When other attempts at life support have failed, it can be an alternative. While ECMO cannot diagnose, treat, or cure a disease, it can benefit patients when their bodies are momentarily unable to give their tissues enough oxygen.

ECMO systems have become smaller and more portable. This pattern intended to increase access to ECMO in a range of clinical situations, including ER visits and hospital transfers. In cases of refractory cardiac arrest where conventional CPR and defibrillation failed, ECMO was increasingly used as a method to support cardiac arrest patients. It was being researched how to use ECMO in pre-hospital and out-of-hospital settings to give patients life-saving support prior to get to the hospital.

ExtraCorporeal Membrane Oxygenation Market Scope

For more details on this report - Request for Sample

ExtraCorporeal Membrane Oxygenation Market Dynamics

The Rising Number of Hospitals Offering ECLS

The rising number of hospitals offering ECMO services and rising number of awareness programs are some of the factors boosting the market growth. For instance, The Extracorporeal Membrane Oxygenation (ECMO) programme at the Mayo Clinic provides treatment for infants, kids, and adults with serious heart or lung diseases. While a person heals, ECMO takes over for the heart, the lungs, or both.

For those who are not benefiting from conventional forms of life support, such as medication or a ventilator, ECMO may be an alternative. To assist critical care medical professionals across the world in learning the most recent ECMO techniques and technology, Mayo Clinic frequently offers classes and training in simulation labs.

Moreover, on May 02, 2022, Extracorporeal membrane oxygenation (ECMO) was used to treat 1,000th patient, according to Cincinnati Children's Hospital Medical Centre. In order to give babies, kids, and adults with life-threatening heart, lung, or both conditions the chance to relax and heal, ECMO is a type of life support. Here in Cincinnati, ECMO has saved many lives, including those of very ill newborns and kids with respiratory conditions or sepsis who were unable to get medical treatment in the paediatric intensive care unit. Thus, all of these factors aid in accelerating market expansion.

The Strategies Adopted by the Companies

The strategies like product launches, product approvals, partnerships and others about the products which helps to boost the market growth. For instance, in May 2023, the 34th Annual ELSO Conference in Seattle, Washington, which is scheduled to take place between September 28 and October 1, 2023, is the largest extracorporeal life support organisation (ELSO) conference in the world. Inspira Technologies OXY B.H.N. Ltd, a company striving to change acute respiratory care, that it will unveil the new ALICE device there. It is a significant accomplishment for the company and the first step towards Inspira's market entry that the ALICE medical device was introduced to the medical community at the ELSO conference in the United States. 

Moreover, on April 25, 2023, the U.S. Food and Drug Administration (FDA) approved Abbott two new certifications for the company's market-leading life support system. The CentriMag Blood Pump for use with the CentriMag System is now approved for longer-term usage in adults who require extracorporeal membrane oxygenation (ECMO), a form of life support for those whose hearts and lungs aren't functioning. Thus, all of the above factors support market expansion.

Cost Associated with the System

Respiratory therapists, and critical care nurses are among the highly skilled and specialised healthcare workers needed for the intricate ECMO treatment. Their experience raises the price overall. Patients on ECMO require ongoing monitoring and care, which includes managing potential problems and making periodic modifications to the ECMO circuit and anticoagulant therapy. 

Dedicated staff and resources are needed for this. ECMO patients require intensive care unit (ICU) services, such as ventilators, drugs, and round-the-clock nursing care. The cost of ICU care is usually high. Not every medical facility offers ECMO. Transporting patients to facilities with ECMO capabilities is frequently necessary, and this can be expensive.

ExtraCorporeal Membrane Oxygenation Market Segment Analysis

The global extracorporeal membrane oxygenation market is segmented based on type, age group, application, end user and region.

Due to the Rising Frequency of the Respiratory Diseases

When conventional mechanical ventilation techniques are unable to deliver enough oxygenation and ventilation in situations with severe ARDS, ECMO is usually used. A number of factors, including as infections (such as pneumonia), trauma, or aspiration, can lead to ARDS. Due to the rising frequency of the target diseases, the high demand for early detection and diagnostic imaging, and the developments in the ECMO machine market, the respiratory segment is predicted to dominate the market. 

Additionally, the need for medical imaging for diagnosis is growing due to the rising occurrence of lung disorders such tuberculosis, thoracic malignancies, osteoporosis, lung transplants, and CVDs.For instance, according to Scientific Registry of Transplant Recipients, stated that, in 2021, 2,569 lung transplants were performed, of which 506 were single and 2,063 were bilateral. 

There were 1,171 transplants performed on recipients between the ages of 50 and 64, 933 on recipients 65 or older, and 440 on recipients between the ages of 18 and 49. In light of a larger percentage of male candidates listed for transplant and a higher waitlist death rate compared to girls, more males than females underwent transplants. Thus, all of the above elements support the segment's growth.

ExtraCorporeal Membrane Oxygenation Market Geographical Share

Increasing Product Approvals and Product Launches in the North American Region

Due to the rising frequency of cardiovascular and respiratory disorders, technological developments in ECMO technology, and greater use of ECMO systems, North America dominated the global market and generated the most revenue share. For instance, according to the data published by the Centers for Disease Control and Prevention (CDC), In the United States, 659,000 individuals are predicted to pass away from heart disease annually in February 2022, accounting for one in every four fatalities. In addition, over 805,000 Americans get heart attacks each year. 

The region's requirement for Extracorporeal Membrane Oxygenation (ECMO) is also rising as a result of changing living habits and greater adoption of innovative technological products that cause chronic diseases like cardiac and respiratory conditions. A considerable amount of output for hospitals has been produced as a result of a rise in the number of developments and advanced innovations in these Extracorporeal Membrane Oxygenation (ECMO) devices as well as a growth in public awareness of their numerous applications.

Additionally, the extracorporeal membrane oxygenation device market in Asia-Pacific is anticipated to develop at the quickest rate during the forecast period. The increase in healthcare spending by the government and commercial organisations to develop healthcare facilities is one of the main reasons fueling the expansion of this region.

COVID-19 Impact Analysis

When traditional mechanical ventilation is insufficient to treat severe cases of COVID-19 respiratory distress, some patients need ECMO support. In areas with high infection rates, the pandemic caused a spike in demand for ECMO services. Resources in the healthcare industry, such as specialized machinery, skilled employees, and ICU beds, were under pressure due to the rising demand for ECMO. 

The increasing number of COVID-19 patients requiring ECMO required hospitals to devote greater resources to their care. The COVID-19 pandemic stimulated more study, development, and research into ECMO technology and procedures. Researchers and medical professionals cooperated to advance ECMO methods and exchange best practices for handling COVID-19 patients on ECMO.

Key Developments

• In November 17, 2022, the FDA approved LifeSPARC, the company's next-generation Advanced Circulatory Support (ACS) pump and controller system, 510(k) clearance for extracorporeal membrane oxygenation (ECMO). LivaNova PLC is a market-leading medical technology and innovation company. With the help of data gathered during the COVID-19 pandemic and other real-world evidence, LivaNova was able to obtain this new indication.
• On August 10, 2021, the launch of the extracorporeal life support system Rotaflow II by Getinge. The new Rotaflow II System from Getinge is much more than just a replacement for the previous Rotaflow System; it also represents a brand-new idea with a number of clever features. Both veno-arterial (VA) and veno-venous (VV) extracorporeal membrane oxygenation (ECMO) can be performed with it.
• On October 04, 2021, MicroPort invests in the expansion of its German operations and purchases the German ECLS company Hemovent GmbH. For a total cash consideration of up to €123 million, MicroPort Scientific Corporation has acquired 100% of the stock owned by current shareholders of Hemovent GmbH (hereafter referred to as "Hemovent") through its critical care subsidiary, MicroPort Surgical B.V. company.

ExtraCorporeal Membrane Oxygenation Market Companies

The major global players in the market include Terumo Corporation, Medtronic Plc, Spectrum Medical, Getinge Inc, OriGen Biomedical, MicroPort Scientific Corporation, XENIOS AG, MC3 Cardiopulmonary, Abiomed Inc, Hemovent GmbH and among others.

Why Purchase the Report?

• To visualize the global extracorporeal membrane oxygenation market segmentation based on type, age group, application, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of extracorporeal membrane oxygenation market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global extracorporeal membrane oxygenation market report would provide approximately 61 tables, 58 figures and 186 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies